UK markets closed


Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
11.80-0.22 (-1.83%)
At close: 5:29PM CEST
Full screen
Previous close12.02
Bid11.74 x 0
Ask11.78 x 0
Day's range11.68 - 12.00
52-week range10.06 - 19.00
Avg. volume72,235
Market cap401.08M
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-1.34
Earnings date25 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy

    UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001) with the primary objective to study safety of NanoZolid®-docetaxel in solid tumors. The data collected in the trial demonstrates safety and tolerability, an active and local drug release of docetaxel over an extended period of time and signs of clinical effect in injected tumors. LIDDS plan to communicate the topline results from the study in Q4 2021. “We

  • Globe Newswire

    LIDDS patent covering the NanoZolid® production process granted in Russia and Australia

    UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in Russia and Australia. The patent provides protection until 2037 in these markets. “This patent is central to LIDDS and significantly broadens our patent protection. The product aspect of the patent improves the ability to detect infringement and it further strengthens our already strong IP portfolio. The decisio

  • Globe Newswire

    LIDDS Interim report January – June 2021

    JANUARY – JUNE 2021 Net sales amounted to MSEK 0.8 (0.0)Operating expenses amounted to MSEK -21.3 (-13.3)Profit/loss before and after tax amounted to MSEK -20.6 (-13.3)Earnings per share amounted to SEK -0.68 (-0.54) Cash flow from operating activities amounted to MSEK -23.5 (-12.1) Equity amounted to MSEK 65.1 (31.7) and the debt/equity ratio was 89% (82%) APRIL – JUNE 2021 Net sales amounted to MSEK 0.1 (0.0)Operating expenses amounted to MSEK -9.9 (-5.3)Profit/loss before and after tax amount